Related Experiment Video
Updated: Mar 20, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Extended duration dual antiplatelet therapy in patients with myocardial infarction: A study-level meta-analysis of
Giuseppe Patti1, Ilaria Cavallari1
1Campus Bio-Medico University of Rome, Rome, Italy.
Insights
Prolonged dual antiplatelet therapy (DAPT) after myocardial infarction (MI) reduces major adverse cardiac events and cardiovascular death. However, it increases nonfatal bleeding risk, especially with potent P2Y12 inhibitors.
Area of Science:
- Cardiology
- Pharmacology
Background:
- The long-term benefits and risks of dual antiplatelet therapy (DAPT) beyond one year after myocardial infarction (MI) remain unclear.
- Previous studies may lack sufficient power to detect rare events like major bleeding or mortality.
Purpose of the Study:
- To assess the long-term effectiveness and safety of prolonged DAPT in patients post-MI.
Main Methods:
- A systematic search identified 3 randomized trials involving 21,534 patients post-MI.
- Patients received either placebo or aspirin plus a P2Y12 inhibitor for at least 2 years.
- Outcomes included major adverse cardiac events (MACE), major bleeding, fatal bleeding, and mortality.
Main Results:
- Prolonged DAPT significantly reduced MACE (OR 0.74, P = .005) and cardiovascular mortality (16% reduction).
- A non-significant increase in major bleeding was observed overall (P = .10), but was significant with ticagrelor or prasugrel (OR 2.16).
- Fatal bleeding and noncardiovascular mortality rates were not increased.
Conclusions:
- Extended DAPT post-MI lowers MACE and cardiovascular mortality but increases nonfatal major bleeding risk, particularly with potent P2Y12 antagonists.
- Individualized DAPT duration is crucial, balancing ischemic and bleeding risks.
Background:
Whether dual antiplatelet therapy (DAPT) is beneficial beyond 1 year after myocardial infarction (MI) is not demonstrated; in particular, available studies may be individually underpowered for end points at low incidence, that is, major and fatal bleeding or mortality. We thus assessed the effectiveness and safety of prolonged DAPT after MI over the long term.
Methods:
We conducted a systematic search to identify randomized trials on the topic; 3 studies and 21,534 post-MI patients receiving placebo or aspirin plus P2Y12 inhibition for ≥2 years were included. Incidence of the following outcome measures was evaluated: major adverse cardiac events (MACE), major bleeding, fatal bleeding, and cardiovascular and noncardiovascular death.
Results:
Occurrence of MACE was lower in patients treated with prolonged DAPT: 6.3% vs 7.9% in those without prolonged DAPT (odds ratios 0.74, 95% CI 0.60-0.91, P = .005); in the former, there was also a significant 16% reduction in cardiovascular mortality. Increase in major bleeding with extended duration DAPT was not significant in the overall analysis (1.5% vs 1.0%; P = .10), but became significant in the analysis restricted to patients receiving ticagrelor or prasugrel as second antiplatelet agent (odds ratios 2.16, 95% CI 1.63-2.86); prolonged use of DAPT did not raise rates of fatal bleeding or noncardiovascular mortality.
Conclusion:
Prolonged DAPT after MI reduces MACE and cardiovascular mortality over the long term; this was paralleled by higher risk of nonfatal major bleeding mainly with the newer, more potent P2Y12 antagonists. Tailoring duration of DAPT after MI on the comparative evaluation of both ischemic and bleeding risk is mandatory in this setting.
More Related Videos
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Peripheral Artery Disease III: Interprofessional Care
01:14Myocarditis III: Medical Management
01:26Angina IV: Management